Our preclinical R&D is a key factor in the successful development of Sensorion.
Our scientific expertise comes from many years of international research experience in the inner ear field. This has allowed us to develop a translational Research and Development platform dedicated to dysfunction of the inner ear incorporating the most recent scientific advances in the field.
This technological platform is used in the development of drugs treating inner ear diseases and has the following features:
Natural or damaged cell or tissue preparations (cochlear or vestibular) are used:
Animal models of the inner ear dysfunction are used to produce translational pharmacodynamic and pharmacokinetic information with the aim of selecting the best candidate drugs and guide their clinical development. We currently have four main types of animal models which allow us to work on selection and development of candidate drugs.
|Models of permanent unilateral vestibular damage||
Treatments for vertigo
|Models of transient unilateral vestibular damage||
Treatments for vertigo
Protective treatments against the chronic effects of infection or an ischemic or traumatic event to the vestibular apparatus
|Models of transient or permanent hearing loss following acoustic trauma||
Preservation or restoration of auditory function
|Models of drug induced ototoxic damage||
Prevention of the injury from secondary effects of medical drugs
Our platform combines a range of knowledge spanning in vitro cell and tissue tests to more complete animal models, in which the diseases and symptoms in human beings are reproduced. This allows us to advance from research and assessment into the potential of specific therapeutic targets to selection and characterisation of the best possible candidate drugs using translational measures.
Our development programmes meet identified but, as of yet, unmet medical needs. Our differentiating development strategy is based on repurposing well described existing compounds already having successfully advanced through one or more timeconsuming preclinical or clinical development stages. This strategy offers a dual advantage:
We currently have three distinct programmes based on three therapeutic targets involved in different inner ear diseases. The selection of the first candidate drugs (First –in-class), represents a portfolio of products to be developed through their clinical phases.
Our future main ambitions are :
We aim to use our unique R&D platform and state of the art know-how to develop candidate drugs, either alone or in partnership with other pharmaceutical companie.